Which of the following is a characteristic of T lymphocytes? a. Phagocytosis of bacteria b. ...

Author Question: Which of the following is a characteristic of T lymphocytes? a. Phagocytosis of bacteria b. ... (Read 21 times)

haleyc112

Hero Member
Posts: 600

on: Jun 25, 2018

Which of the following is a characteristic of T lymphocytes?

a. Phagocytosis of bacteria
b. Antibody synthesis
c. Cytokine secretion
d. Few in number within peripheral blood

Question 2

The lymphoid progenitor that gives rise to T, B, and NK lymphocytes is recognized as which of the following?

a. CFU_GM
b. CLP
c. CMP
d. CFU-T

xthemafja

Sr. Member
Posts: 348

Reply #1 on: Jun 25, 2018

Answer to Question 1

Correct Answer: C

Answer to Question 2

Correct Answer: B

Need homework help now?

Ask unlimited questions for free

Ask a Question

« previous next »

Did you know?

GI conditions that will keep you out of the U.S. armed services include ulcers, varices, fistulas, esophagitis, gastritis, congenital abnormalities, inflammatory bowel disease, enteritis, colitis, proctitis, duodenal diverticula, malabsorption syndromes, hepatitis, cirrhosis, cysts, abscesses, pancreatitis, polyps, certain hemorrhoids, splenomegaly, hernias, recent abdominal surgery, GI bypass or stomach stapling, and artificial GI openings.

Did you know?

Bacteria have flourished on the earth for over three billion years. They were the first life forms on the planet.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Studies show that systolic blood pressure can be significantly lowered by taking statins. In fact, the higher the patient's baseline blood pressure, the greater the effect of statins on his or her blood pressure.

Did you know?

In Eastern Europe and Russia, interferon is administered intranasally in varied doses for the common cold and influenza. It is claimed that this treatment can lower the risk of infection by as much as 60–70%.